Similarities and differences between biliary sludge and microlithiasis: Their clinical and pathophysiological significances
December 2018
The terms biliary sludge and cholesterol microlithiasis (hereafter referred to as microlithiasis) were originated from different diagnostic techniques and may represent different stages of cholesterol...
Share article
Hepatocellular carcinoma recurrence: Predictors and management
December 2023
Hepatocellular carcinoma (HCC), the sixth most common cancer globally, is associated with high mortality rates and more than 830,000 annual deaths. Despite advances in the available management options...
Share article
Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target
December 2022
Non-alcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease worldwide, and is closely associated with the increased risk of the prevalence of obesity and diabetes....
Share article
Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do
June 2024
Hepatitis B virus (HBV) infection is a significant health problem that can result in progression to liver cirrhosis, decompensation, and the development of hepatocellular carcinoma (HCC). On a country...
Share article
Chinese expert consensus on refined diagnosis, treatment, and management of advanced primary liver cancer (2023 edition)
June 2024
Hepatocellular carcinoma (HCC), commonly known as primary liver cancer, is a major cause of malignant tumors and cancer-related deaths in China, accounting for approximately 85% of all cancer cases...
Share article
Vitamins and non-alcoholic fatty liver disease: A molecular insight
June 2021
The incidence of non-alcoholic fatty liver disease (NAFLD) is rising rapidly across the globe. NAFLD pathogenesis is largely driven by an imbalance in hepatic energy metabolism, and at present, there...
Share article
Role of immune cell interactions in alcohol-associated liver diseases
June 2024
Research on inflammatory response, liver injury, and immune regulation has demonstrated that the intricate interactions among immune cells constitute a critical regulatory network. Alcohol consumption...
Share article
Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis
June 2020
Cholesterol 7 alpha-hydroxylase (CYP7A1, EC1.14) is the first and rate-limiting enzyme in the classic bile acid synthesis pathway. Much progress has been made in understanding the transcriptional regulation...
Share article
Radiofrequency ablation of hepatocellular carcinoma: Current status, challenges, and prospects
June 2023
Local ablation technologies, such as radiofrequency ablation (RFA), microwave ablation (MWA) and cryoablation, have become a standard treatment option for hepatocellular carcinoma (HCC) less than 5 cm...
Share article
Unveiling the effect of estrogen receptors in alcoholic liver disease: A novel outlook
December 2023
Alcoholic liver disease (ALD) has a multifaceted development, progressing from alcoholic steatosis to alcoholic hepatitis and ultimately to alcoholic cirrhosis, irreversible liver damage that can even...
Share article
Clinical perspectives of isoniazid-induced liver injury
June 2021
Isoniazid (INH) is a synthetic anti-mycobacterial agent used to treat active or latent tuberculosis (TB). INH has been in clinical use for nearly 70 years and remains broadly utilized at the front line...
Share article
In-depth analysis of de novo lipogenesis in non-alcoholic fatty liver disease: Mechanism and pharmacological interventions
December 2023
Non-alcoholic fatty liver disease (NAFLD) is characterized by the abnormal buildup of lipids in the liver tissue. Non-alcoholic fatty liver (NAFL) may progress to non-alcoholic steatohepatitis. Triglycerides...
Share article
Physical activity and exercise in liver cancer
March 2024
Sarcopenia and physical deconditioning are common complications in patients with liver cancer, which are frequently caused by insufficient physical activity and poor nutritional status, resulting in...
Share article
Alcoholic liver disease: A current molecular and clinical perspective
December 2018
Heavy alcohol use is the cause of alcoholic liver disease (ALD). The ALD spectrum ranges from alcoholic steatosis to steatohepatitis, fibrosis, and cirrhosis. In Western countries, approximately 50%...
Share article
Viral hepatitis E: Clinical manifestations, treatment, and prevention
March 2024
Hepatitis E is a globally distributed infection that varies in seroprevalence between developed and developing regions. In the less developed regions of Asia and Africa, a high seropositivity rate has...
Share article
Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma
December 2020
Hepatocellular carcinoma (HCC) is a malignant tumor with a fairly poor prognosis (5-year survival of less than 50%). Using sorafenib, the only food and drug administration (FDA)-approved drug, HCC cannot...
Share article
Plasma microRNA-15a/16-1-based machine learning for early detection of hepatitis B virus-related hepatocellular carcinoma
June 2024
Hepatocellular carcinoma (HCC), which is prevalent worldwide and has a high mortality rate, needs to be effectively diagnosed. We aimed to evaluate the significance of plasma microRNA-15a/16-1 (miR-15a/16)...
Share article
Early plasma exchange and continuous renal replacement therapy improve puerperal prognosis in hepatitis B virus-related acute-on-chronic liver failure in pregnancy
June 2024
Hepatitis B virus (HBV)-related gestational acute-on-chronic liver failure (ACLF) is a severe condition with limited treatment options. This study aimed to evaluate the efficacy and ideal timing of...
Share article
Current and emerging therapies for alcohol-associated hepatitis
March 2023
Alcohol-related liver disease (ALD) encompasses a spectrum of diseases caused by excessive alcohol consumption. ALD includes hepatic steatosis, steatohepatitis, variable degrees of fibrosis, cirrhosis,...
Share article
Liver-specific glucocorticoid action in alcoholic liver disease: Study of glucocorticoid receptor knockout and knockin mice
June 2024
Glucocorticoids are the only first-line drugs for severe alcoholic hepatitis (AH), with limited efficacy and various side effects on extrahepatic tissues. Liver-targeting glucocorticoid therapy may...
Share article
Share article
Dysregulation of glutathione synthesis in liver disease
June 2020
Glutathione (GSH), a tripeptide that is present in all mammalian tissues, is especially highly concentrated in the liver. GSH synthesis occurs via two adenosine triphosphate (ATP)-requiring enzymatic...
Share article
Telehealth interventions for alcohol use disorder: A systematic review
September 2022
Alcohol use disorder (AUD) is a worldwide problem for individuals of varying ages and backgrounds and is associated with the underlying cause of alcoholic liver disease, liver cirrhosis, liver cancer,...
Share article
Immune cells in alcohol-related liver disease
March 2022
Alcohol-related liver disease (ALD), which is caused by excessive alcohol consumption, is one of the most common types of liver disease and a primary cause of hepatic injury, with a disease spectrum...
Share article
Non-alcoholic fatty liver disease: Dietary and nutraceutical approaches
September 2023
Non-alcoholic fatty liver disease (NAFLD), defined as the presence of fat accumulation in imaging or histology in more than 5% of hepatocytes and exclusion of other causes for secondary hepatic fat...
Share article
